Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma

American Journal of Neuroradiology

Volumn 35, Issue 4, 2014, Pages 673-679

  Ellingson, Benjamin M ^a   Sahebjam, S ^b   Kim, H J ^a   Pope, W B ^a   Harris, R J ^a   Woodworth, D C ^a   Lai, A ^a   Nghiemphu, P L ^a   Mason, W P ^b   Cloughesy, T F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; GLIOBLASTOMA; HISTOGRAM; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MONOTHERAPY; NORMAL DISTRIBUTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BRAIN NEOPLASMS; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MONITORING; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG MONITORING; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84898435813     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3748     Document Type: Article

References (24)

1. Central Brain Tumor Registry of the United States. CBTRUS Statistical Report Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT- Final-3-2-10.pdf. Accessed January 2013
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96 (Pubitemid 40349501)
3. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-78 (Pubitemid 29368260)
4. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207-18 (Pubitemid 24261926)
5. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-79
6. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-98 (Pubitemid 29309448)
7. Pope WB, Young JR, Ellingson BM. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011;11:336-44
8. Leu K, Pope WB, Cloughesy TF, et al. Imaging biomarkers for anti-angiogenic therapy in malignant gliomas. CNS Oncology 2013;2:33-47
9. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-89
10. Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882-89
11. Ellingson BM, Bedekar DP, Malkin MG, et al. Hybrid functional diffusion and perfusion maps for evaluation of gliomas. In: Proceedings of the 17th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Honolulu, Hawaii. April 18-24, 2009;17:1000
12. Ellingson BM, Cloughesy TF, Lai A, et al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:1151-61
13. Ellingson BM, Cloughesy TF, Lai A, et al. Cell invasion, motility, and proliferation level estimate (CIMPLE)mapsderived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011;105:91-101
14. Ellingson BM, Cloughesy TF, Lai A, et al. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med 2012;67:237-45
15. Kothari PD, White NS, Farid N, et al. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. AJNR Am J Neuroradiol 2013;34:1752-57
16. White NS, McDonald CR, Farid N, et al. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high B-value DWI and ADC. AJNR Am J Neuroradiol 2013;34:958-64, S1
17. Andre JB, Lu S, Spearman K, et al. Peritumoral apparent diffusion coefficient as a metric of response in patients with recurrent glioblastoma multiforme treated with bevacizumab and irinotecan. NRJ 2008;21:350-61 (Pubitemid 351860982)
18. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28:e91-93
19. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrentGBMtreated with bevacizumab: a multicenter study. J Neurooncol 2012;108:491-98
20. Pope WB, Mirsadraei L, Lai A, et al. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNRAmJ Neuroradiol 2012;33:1059-64
21. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-99
22. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54
23. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-25
24. Gerstner ER, Chen PJ, Wen PY, et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010;12:466-72